Apr 23, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today provided a strategic and operational update and preliminary revenue results for the three months ended March 31, 2018. The...
Apr 6, 2018Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to U.S. FDA-Approved A-101 40% Topical Solution from Aclaris Therapeutics
Transaction broadens Cipher's Canadian dermatology portfolio with first and only prescription product for raised seborrheic keratoses (SKs) MISSISSAUGA, ON, April 6, 2018 /CNW/ - Cipher...
Mar 20, 2018Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome
Cipher to Acquire Cardiome's Canadian Business Portfolio, Comprised of Four Commercial and Pipeline Assets Targeting Cardiovascular and Anti-Infective Indications for Upfront Consideration of...
Feb 28, 2018
90% increase in revenue and 214% increase in income from continuing operations for Q4 2017 Canadian launch of OZANEX™ in Jan 2018 Acquired Canadian rights to TRULANCE® in Feb 2018 MISSISSAUGA, ON,
Feb 28, 2018Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE® from Synergy Pharmaceuticals
A new differentiated treatment option for GI disorders Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market where innovative treatments are needed...